Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY

Open source

DOI: 10.1182/bloodadvances.2024014975
Published: 2025 Dec 9
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2024014975,
  title = {Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.},
  author = {Shah NN and Zinzani PL and Wang M and Nasta SD and Lech-Maranda E and Ogawa Y and Fakhri B and Kuss B and Miyashita K and Patel K and Coombs CC and Ma S and Patel MR and Barve MA and Tessoulin B and Stathis A and Ennishi D and Hashimoto D and Kojima K and Zelenetz AD and Cohen JB and Vose JM and Maddocks KJ and Munir T and Sun F and Bian Y and Balbas M and Tsai DE and Abada P and Cheah CY},
  year = {2025},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2024014975},
  url = {https://doi.org/10.1182/bloodadvances.2024014975}
}

RIS

TY  - JOUR
TI  - Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
AU  - Shah NN
AU  - Zinzani PL
AU  - Wang M
AU  - Nasta SD
AU  - Lech-Maranda E
AU  - Ogawa Y
AU  - Fakhri B
AU  - Kuss B
AU  - Miyashita K
AU  - Patel K
AU  - Coombs CC
AU  - Ma S
AU  - Patel MR
AU  - Barve MA
AU  - Tessoulin B
AU  - Stathis A
AU  - Ennishi D
AU  - Hashimoto D
AU  - Kojima K
AU  - Zelenetz AD
AU  - Cohen JB
AU  - Vose JM
AU  - Maddocks KJ
AU  - Munir T
AU  - Sun F
AU  - Bian Y
AU  - Balbas M
AU  - Tsai DE
AU  - Abada P
AU  - Cheah CY
PY  - 2025
JO  - Blood advances
DO  - 10.1182/bloodadvances.2024014975
UR  - https://doi.org/10.1182/bloodadvances.2024014975
ER  -

APA

NN, S., PL, Z., M, W., SD, N., E, L., Y, O., B, F., B, K., K, M., K, P., CC, C., S, M., MR, P., MA, B., B, T., A, S., D, E., D, H., K, K., AD, Z., JB, C., JM, V., KJ, M., T, M., F, S., Y, B., M, B., DE, T., P, A., & CY, C. (2025). Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.. Blood advances. https://doi.org/10.1182/bloodadvances.2024014975

Source records

pubmed · retrieved 2026-09-26T09:45:33.468Z